Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
Niels Willem Boone, Roelof Wouter Frederik van LeeuwenMaastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The NetherlandsRecently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, rec...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/43edcb1ca8cf4cafa08fd527b225072a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Niels Willem Boone, Roelof Wouter Frederik van LeeuwenMaastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The NetherlandsRecently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, received a request for the aseptic preparation of an alteplase syringe solution for subretinal administration. Looking for dose rationale, our ophthalmology doctor came up with a concentration based on an article published by Arias and colleagues in Clinical Ophthalmology in 2010. |
|---|